metabotropic glutamate receptor 3 (gprc1c or mglur3 or grm3)-pipeline review, h2 2017

metabotropic glutamate receptor 3 (gprc1c or mglur3 or grm3)-pipeline review, h2 2017


  • Products Id :- GMDHC0969TDB
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Pipeline Review, H2 2017

Summary

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Oncology which include indications Depression, Parkinson's Disease, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Chronic Pain, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Glioma, Schizophrenia and Treatment Resistant Depression.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

-The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects

-The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Overview 6

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Companies Involved in Therapeutics Development 18

Addex Therapeutics Ltd 18

Aevi Genomic Medicine Inc 18

Denovo Biopharma LLC 19

Domain Therapeutics SA 19

Eli Lilly and Company 20

Prexton Therapeutics SA 20

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Drug Profiles 21

DT-010991-Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

DT-011088-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

fasoracetam-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

LY-2969822-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

LY-3020371-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

LY-341495-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

pomaglumetad methionil-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Agonize mGluR3 for Parkinson's Disease-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Modulate mGlu3 Receptor for CNS Disorders-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

VU-0092273-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

VU-0650786-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Dormant Products 35

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Discontinued Products 37

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)-Product Development Milestones 38

Featured News & Press Releases 38

May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 38

Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 38

Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 40

Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 40

Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 41

Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 42

Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 42

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 43

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson's disease with renewed support by The Michael J. Fox Foundation 44

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 44

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 45

Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research 45

Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administrations, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 17

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 17

Pipeline by Addex Therapeutics Ltd, H2 2017 18

Pipeline by Aevi Genomic Medicine Inc, H2 2017 18

Pipeline by Denovo Biopharma LLC, H2 2017 19

Pipeline by Domain Therapeutics SA, H2 2017 19

Pipeline by Eli Lilly and Company, H2 2017 20

Pipeline by Prexton Therapeutics SA, H2 2017 20

Dormant Products, H2 2017 35

Dormant Products, H2 2017 (Contd..1), H2 2017 36

Discontinued Products, H2 2017 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Denovo Biopharma LLC

Domain Therapeutics SA

Eli Lilly and Company

Prexton Therapeutics SA

select a license
Single User License
USD 3500 INR 249830
Site License
USD 7000 INR 499660
Corporate User License
USD 10500 INR 749490

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com